DON'T MISS OUT! Next-Generation Genetic Discovery Systems in Human Immune Cells In this November 18th webinar hosted by The CRISPR Journal, one of the developers of pooled knock-in screening, Dr. Theo Roth (Stanford University), will present an overview of this platform and the advantages of non-viral genome targeting. Register now to join us for this free webinar sponsored by MaxCyte, Inc.: https://hubs.li/Q02Wk2bW0
The CRISPR Journal
图书期刊出版业
New Rochelle，New York 5,147 位关注者
Cutting-edge peer-reviewed research and analysis on genome editing and CRISPR biology.
关于我们
CRISPR has captured the imagination of scientists worldwide, not to mention a Nobel Prize in 2020. Applications range from a plethora of basic research fields to diagnosing and curing genetic and infectious diseases and engineering longer-lived crops, and much more. In 2018, Mary Ann Liebert, Inc., publishers announced the creation of The CRISPR Journal -- an international, multidisciplinary peer-reviewed journal publishing outstanding research on the myriad applications and underlying technology of CRISPR and related genome editing platforms. The Journal provides a high-profile venue for groundbreaking peer-reviewed research, as well as lively and provocative commentary, analysis, and debate. Editor-in-Chief: Rodolphe Barrangou, PhD. Executive Editor: Kevin Davies PhD
- 网站
-
https://www.crisprjournal.com
The CRISPR Journal的外部链接
- 所属行业
- 图书期刊出版业
- 规模
- 51-200 人
- 总部
- New Rochelle，New York
- 类型
- 私人持股
- 创立
- 2017
- 领域
- Gene editing technology、CRISPR biology and technology、Host-pathogen interactions、Genetic and infectious diseases、Plant biology、Food science、Zinc fingers and TALENs、Microbial immunity、Cancer immunotherapy、DNA-protein complexes、Gene therapy、Embryonic development、Systems biology、Organ transplantation、Animal models、 IP and patenting、Bioethics、Genetically modified foods、Gene drives和Synthetic biology
地点
-
主要
获取路线
140 Huguenot Street
US，New York，New Rochelle，10801
The CRISPR Journal员工
动态
-
In our latest issue, an extraordinary 6,000-word guest editorial by Fyodor Urnov on the urgent challenges facing the #CRISPR community in translating the potential of gene editing into approved clinical therapies. This is arguably the most important article we have ever published since launch in 2018. (The article is free to read and download for non-subscribers until the end of the year.) https://lnkd.in/gVKrvXjK
-
Our colleagues at Genetic Engineering & Biotechnology News are hosting an exciting new virtual summit on October 30: THE STATE OF AI IN DRUG DISCOVERY Registration is free.
I'm thrilled to be leading GEN's (Genetic Engineering & Biotechnology News) inaugural virtual summit, "The State of AI in Drug Discovery", streaming on October 30th! We have an INCREDIBLE line-up of founders, executives, and researchers to discuss the latest advances, challenges and concerns regarding the deployment of #AI in biotech, with particular emphasis on disrupting the drug discovery process. Check it out ?? ?? A keynote fireside chat with?Najat Khan, PhD?(Recursion) on growing the AI in drug discovery industry ?? A keynote presentation with protein design expert?David Baker (Institute for Protein Design, University of Washington) ?? From computational platforms to protein therapeutics with?Ava Amini (Microsoft Research),?Gevorg Grigoryan (Generate:Biomedicines), and?Karen Akinsanya?(Schr?dinger) ?? Foundational models to read and write the language of biology with?Ali Madani (Profluent),?Brian Hie?(Stanford University), and?Alex Rives?(EvolutionaryScale). ?? Key considerations for AI-based small molecule drug discovery with Jen Nwankwo, Ph.D. (1910 Genetics), Jacob Berlin, PhD (Terray Therapeutics), Philip Tagari (insitro), and Alex Zhavoronkov (Insilico Medicine) ?? AI in drug discovery’s evolving business landscape with?Simon Barnett?(Dimension),?Sabrina Yang?(Empress Therapeutics/Flagship Pioneering), and?Colin Hill?(Aitia) Registration is FREE! Get your spot today! ?? https://lnkd.in/gnGGAK_r
-
-
The June 2024 issue of The CRISPR Journal is online now! https://lnkd.in/g2p8RKR
-
-
Register today for our upcoming half-day virtual summit: THE STATE OF CRISPR and GENE EDITING (June 5, 2024): https://lnkd.in/edv2t5xu
Just announced our outsanding line-up for THE STATE OF CRISPR AND GENE EDITING -- ... a 4.5-hr FREE virtual event on June 5 hosted by Genetic Engineering & Biotechnology News (and me): Guest speakers include David R. Liu, Laura Sepp-Lorenzino, Ph.D., Patrick Hsu, Silvana Konermann, Omar Abudayyeh, Jonathan Gootenberg, Alison Van Eenennaam, Elena Rice, Samuel Sternberg and Joe Bondy-Denomy. #StateCRISPR24 https://lnkd.in/ey3n5JVY
The State of CRISPR and Gene Editing 2024, Wed, Jun 5th, 2024 @ 11:00 AM Mary Ann Liebert, Inc. publishers
webinars.liebertpub.com
-
Register today for our upcoming half-day virtual summit: THE STATE OF CRISPR and GENE EDITING (June 5, 2024): https://lnkd.in/edv2t5xu
Just announced our outsanding line-up for THE STATE OF CRISPR AND GENE EDITING -- ... a 4.5-hr FREE virtual event on June 5 hosted by Genetic Engineering & Biotechnology News (and me): Guest speakers include David R. Liu, Laura Sepp-Lorenzino, Ph.D., Patrick Hsu, Silvana Konermann, Omar Abudayyeh, Jonathan Gootenberg, Alison Van Eenennaam, Elena Rice, Samuel Sternberg and Joe Bondy-Denomy. #StateCRISPR24 https://lnkd.in/ey3n5JVY
The State of CRISPR and Gene Editing 2024, Wed, Jun 5th, 2024 @ 11:00 AM Mary Ann Liebert, Inc. publishers
webinars.liebertpub.com
-
We're hosting a really exciting webinar on April 4 on the application of INDUCE-seq to validate the safety of CRISPR gene editing. It is sponsored and presented by Broken String Biosciences and hosted by Executive Editor Kevin Davies. Registration is free! https://lnkd.in/eM6M6Unh
Cell therapy developers, have you registered for our free webinar with The CRISPR Journal on Thursday 4th April? Assays for assessing the safety of gene editing therapies using CRISPR, and other gene editing technologies, lack the sensitivity needed to fully evaluate potential off-target effects. Join our CEO, Felix Dobbs, PhD, and CSO, Prof. Simon Reed, alongside Alberto del Río Espínola, PhD (GentiBio) to explore our game-changing technology, INDUCE-seq, and find out how it can inform safer gene editing for developing the next generation of #celltherapies. Register here: https://bit.ly/3Ter1R5
-
-
Online now: Our first issue in our 7th year of publishing. https://lnkd.in/e82YZGwR We feature an exclusive interview with Victoria Gray, the sickle cell warrior who pioneered the first CRISPR-based cell therapy, launching the clinical trial that won approval last year as Casgvey, sponsored by Vertex Pharmaceuticals and CRISPR Therapeutics. Also in this issue: a landmark study from Genus PLC in safeguarding pigs from a major virus; and a rapid workflow using prime editing to create mutations in iPSCs, developed by National Human Genome Research Institute (NHGRI) researchers including Lori Bonnycastle and former NIH director Francis Collins.
The CRISPR Journal | Vol 7, No 1
liebertpub.com